Among First Countries to Roll Out Groundbreaking HIV Prevention Drug
23 September 2025
Spread the love
Harare The United States Embassy in Harare has announced that Zimbabwe is one of just ten countries worldwide selected to roll out lenacapavir, a twice-yearly HIV prevention medicine hailed as a “breakthrough” in the global fight against the epidemic.
According to a pre-statement released by the embassy, the new programme will see lenacapavir introduced in Zimbabwe through a partnership with U.S.-based pharmaceutical company Gilead Sciences and the Global FundYes Zimbabwe, it’s happening! … We’re delivering lenacapavir, the first twice-yearly HIV prevention medicine,” the Embassy stated.
Why This Matters
U.S. Embassy: “American Leadership at Its Best”
The embassy described the rollout as a landmark moment in U.S.–Zimbabwe health cooperation, saying it “advances a pathway to a safer, stronger, and healthier future” and represents “American leadership at its best.”
The statement emphasized that the programme is more than just medicine — it is an investment in community resilience, prevention, and long-term healthcare capacity.Zimbabwe has one of the highest HIV prevalence rates in the region but has also been recognized for its successful national prevention programmes.
Experts believe that a twice-yearly injectable preventive therapy could drastically reduce new infections and ease the burden on healthcare providers.US Selects Zimbabwe Chosen Among First Countries to Roll Out Groundbreaking HIV Prevention Drug
